The tweet was deleted by the author.
But we saved everything 🙂.
Biogen is presenting updated data and scientific progress from its spinal muscular atrophy (SMA) treatment pipeline at the 2026 MDA Conference, hosted by the Muscular Dystrophy Association, and at the SMA Europe forum.
The company aims to advance research in SMA, highlighting clinical developments that could impact future treatment strategies for the neuromuscular community. Details about specific breakthroughs or outcomes have not yet been disclosed as the presentations are ongoing.
View post on X Loading...
Biogen's renewed commitment to neuromuscular research at major clinical forums builds on the company's broader strategic initiatives. These efforts align with the disciplined approach highlighted in its Q4 and full-year earnings, where Biogen underscored both operational focus and forward-looking investments in innovation.